atreleuton

arachidonate 5-lipoxygenase ; Homo sapiens







12 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 31983575 Effect of 5-lipoxygenase inhibitor, VIA-2291 (Atreleuton), on epicardial fat volume in patients with recent acute coronary syndrome. 2020 Jul - Aug 1
2 27883201 Effect of treatment with 5-lipoxygenase inhibitor VIA-2291 (atreleuton) on coronary plaque progression: a serial CT angiography study. 2017 Apr 2
3 25752438 A phase 2 randomized, double-blind, placebo-controlled study of the effect of VIA-2291, a 5-lipoxygenase inhibitor, on vascular inflammation in patients after an acute coronary syndrome. 2015 May 1
4 20190281 Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. 2010 May 2
5 11527015 ABT-761 (Abbott). 2001 Jan 1
6 9569998 Dose-proportional pharmacokinetics of a new 5-lipoxygenase inhibitor, ABT-761, in healthy volunteers. 1998 Apr 2
7 9596112 Effects of a 5-lipoxygenase inhibitor, ABT-761, on exercise-induced bronchoconstriction and urinary LTE4 in asthmatic patients. 1998 Mar 2
8 9702850 Effects of ABT-761, a novel 5-lipoxygenase inhibitor, on the pharmacokinetics of a single dose of ethinyl estradiol and levonorgestrel in healthy female volunteers. 1998 Jul 2
9 9923573 Pharmacokinetics of a novel 5-lipoxygenase inhibitor (ABT-761) in pediatric patients with asthma. 1998 Nov-Dec 1
10 10099073 Lack of cytochrome P450 1A2 interaction effect of ABT-761 on the pharmacokinetics of theophylline. 1998 Sep 1
11 9117020 The effect of ABT-761, a novel 5-lipoxygenase inhibitor, on exercise- and adenosine-induced bronchoconstriction in asthmatic subjects. 1997 Mar 1
12 9311617 Improving the in vivo duration of 5-lipoxygenase inhibitors: application of an in vitro glucuronosyltransferase assay. 1997 Sep 1